vs
Side-by-side financial comparison of BEYOND MEAT, INC. (BYND) and Vericel Corp (VCEL). Click either name above to swap in a different company.
Vericel Corp is the larger business by last-quarter revenue ($92.9M vs $61.6M, roughly 1.5× BEYOND MEAT, INC.). On growth, Vericel Corp posted the faster year-over-year revenue change (23.3% vs -19.7%). Vericel Corp produced more free cash flow last quarter ($12.8M vs $-49.8M). Over the past eight quarters, Vericel Corp's revenue compounded faster (34.6% CAGR vs -9.7%).
Beyond Meat, Inc., branded as Beyond, is a producer of plant-based meat alternatives founded in 2009 by Ethan Brown. The company's products were first launched in the United States in 2012.
Vericel Corporation is a publicly traded American biopharmaceutical company which was known prior to October 2014 as Aastrom Bio. Aastrom Bio was formed in 1989 in Ann Arbor, Michigan.
BYND vs VCEL — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $61.6M | $92.9M |
| Net Profit | — | $23.2M |
| Gross Margin | -11.5% | 78.7% |
| Operating Margin | -211.4% | 24.1% |
| Net Margin | — | 25.0% |
| Revenue YoY | -19.7% | 23.3% |
| Net Profit YoY | — | 17.3% |
| EPS (diluted) | $0.68 | $0.46 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $61.6M | $92.9M | ||
| Q3 25 | $70.2M | $67.5M | ||
| Q2 25 | $75.0M | $63.2M | ||
| Q1 25 | $68.7M | $52.6M | ||
| Q4 24 | $76.7M | $75.4M | ||
| Q3 24 | $81.0M | $57.9M | ||
| Q2 24 | $93.2M | $52.7M | ||
| Q1 24 | $75.6M | $51.3M |
| Q4 25 | — | $23.2M | ||
| Q3 25 | $-110.7M | $5.1M | ||
| Q2 25 | $-29.2M | $-553.0K | ||
| Q1 25 | $-52.9M | $-11.2M | ||
| Q4 24 | — | $19.8M | ||
| Q3 24 | $-26.6M | $-901.0K | ||
| Q2 24 | $-34.5M | $-4.7M | ||
| Q1 24 | $-54.4M | $-3.9M |
| Q4 25 | -11.5% | 78.7% | ||
| Q3 25 | 10.3% | 73.5% | ||
| Q2 25 | 11.5% | 73.7% | ||
| Q1 25 | -1.5% | 69.0% | ||
| Q4 24 | 13.1% | 77.6% | ||
| Q3 24 | 17.7% | 71.9% | ||
| Q2 24 | 14.7% | 69.5% | ||
| Q1 24 | 4.9% | 68.9% |
| Q4 25 | -211.4% | 24.1% | ||
| Q3 25 | -160.0% | 5.1% | ||
| Q2 25 | -46.6% | -3.2% | ||
| Q1 25 | -81.8% | -24.3% | ||
| Q4 24 | -49.3% | 24.5% | ||
| Q3 24 | -38.2% | -4.3% | ||
| Q2 24 | -36.4% | -11.5% | ||
| Q1 24 | -70.7% | -10.7% |
| Q4 25 | — | 25.0% | ||
| Q3 25 | -157.6% | 7.5% | ||
| Q2 25 | -39.0% | -0.9% | ||
| Q1 25 | -77.0% | -21.4% | ||
| Q4 24 | — | 26.3% | ||
| Q3 24 | -32.8% | -1.6% | ||
| Q2 24 | -37.0% | -8.9% | ||
| Q1 24 | -71.9% | -7.5% |
| Q4 25 | $0.68 | $0.46 | ||
| Q3 25 | $-1.44 | $0.10 | ||
| Q2 25 | $-0.38 | $-0.01 | ||
| Q1 25 | $-0.69 | $-0.23 | ||
| Q4 24 | $-0.65 | $0.40 | ||
| Q3 24 | $-0.41 | $-0.02 | ||
| Q2 24 | $-0.53 | $-0.10 | ||
| Q1 24 | $-0.84 | $-0.08 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $203.9M | $137.5M |
| Total DebtLower is stronger | $415.7M | — |
| Stockholders' EquityBook value | $-997.0K | $354.6M |
| Total Assets | $614.7M | $488.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $203.9M | $137.5M | ||
| Q3 25 | $117.3M | $135.4M | ||
| Q2 25 | $103.5M | $116.9M | ||
| Q1 25 | $102.1M | $112.9M | ||
| Q4 24 | $131.9M | $116.2M | ||
| Q3 24 | $121.7M | $101.7M | ||
| Q2 24 | $144.9M | $102.5M | ||
| Q1 24 | $157.9M | $110.6M |
| Q4 25 | $415.7M | — | ||
| Q3 25 | $1.2B | — | ||
| Q2 25 | $1.2B | — | ||
| Q1 25 | $1.1B | — | ||
| Q4 24 | $1.1B | — | ||
| Q3 24 | $1.1B | — | ||
| Q2 24 | $1.1B | — | ||
| Q1 24 | $1.1B | — |
| Q4 25 | $-997.0K | $354.6M | ||
| Q3 25 | $-784.1M | $321.9M | ||
| Q2 25 | $-677.0M | $306.8M | ||
| Q1 25 | $-649.5M | $295.5M | ||
| Q4 24 | $-601.2M | $292.0M | ||
| Q3 24 | $-611.9M | $257.5M | ||
| Q2 24 | $-590.0M | $243.0M | ||
| Q1 24 | $-561.4M | $233.9M |
| Q4 25 | $614.7M | $488.0M | ||
| Q3 25 | $599.7M | $453.3M | ||
| Q2 25 | $691.7M | $435.6M | ||
| Q1 25 | $643.8M | $424.6M | ||
| Q4 24 | $678.1M | $432.7M | ||
| Q3 24 | $692.9M | $390.4M | ||
| Q2 24 | $711.2M | $376.8M | ||
| Q1 24 | $735.0M | $356.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-46.8M | $15.0M |
| Free Cash FlowOCF − Capex | $-49.8M | $12.8M |
| FCF MarginFCF / Revenue | -80.8% | 13.8% |
| Capex IntensityCapex / Revenue | 4.8% | 2.4% |
| Cash ConversionOCF / Net Profit | — | 0.65× |
| TTM Free Cash FlowTrailing 4 quarters | $-157.2M | $24.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-46.8M | $15.0M | ||
| Q3 25 | $-38.8M | $22.1M | ||
| Q2 25 | $-33.2M | $8.2M | ||
| Q1 25 | $-26.1M | $6.6M | ||
| Q4 24 | $-29.0M | $22.2M | ||
| Q3 24 | $-22.0M | $10.2M | ||
| Q2 24 | $-16.0M | $18.5M | ||
| Q1 24 | $-31.8M | $7.2M |
| Q4 25 | $-49.8M | $12.8M | ||
| Q3 25 | $-41.7M | $19.5M | ||
| Q2 25 | $-35.1M | $81.0K | ||
| Q1 25 | $-30.6M | $-7.6M | ||
| Q4 24 | $-35.4M | $8.5M | ||
| Q3 24 | $-24.1M | $-9.2M | ||
| Q2 24 | $-17.3M | $1.8M | ||
| Q1 24 | $-33.0M | $-6.8M |
| Q4 25 | -80.8% | 13.8% | ||
| Q3 25 | -59.4% | 28.8% | ||
| Q2 25 | -46.9% | 0.1% | ||
| Q1 25 | -44.6% | -14.5% | ||
| Q4 24 | -46.2% | 11.2% | ||
| Q3 24 | -29.7% | -15.9% | ||
| Q2 24 | -18.6% | 3.4% | ||
| Q1 24 | -43.7% | -13.3% |
| Q4 25 | 4.8% | 2.4% | ||
| Q3 25 | 4.1% | 3.9% | ||
| Q2 25 | 2.6% | 12.9% | ||
| Q1 25 | 6.5% | 27.0% | ||
| Q4 24 | 8.4% | 18.3% | ||
| Q3 24 | 2.5% | 33.5% | ||
| Q2 24 | 1.4% | 31.8% | ||
| Q1 24 | 1.6% | 27.3% |
| Q4 25 | — | 0.65× | ||
| Q3 25 | — | 4.35× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 1.12× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BYND
Segment breakdown not available.
VCEL
| MACI Implants And Kits | $84.1M | 90% |
| Other | $8.8M | 10% |
